CD40 Targeted Peptides Inhibit CD154 Interaction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for modulating CD40 interactions are inadequate in achieving long-term tolerance in transplant settings and managing inflammatory and autoimmune diseases, as they fail to effectively inhibit the CD40-CD154 interaction, leading to immune response activation and rejection.
Innovation Solution
A pharmaceutical composition comprising peptides with specific amino acid sequences (at least 85-90% identity to SEQ ID NOs: 1-17) that bind to CD40, inhibiting its interaction with CD154, formulated with a pharmaceutically acceptable carrier, and administered in various forms including liposomes or nanoparticles for targeted delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods for modulating CD40 interactions are used, then the CD40-CD154 interaction is not effectively inhibited, but this leads to immune response activation and rejection
Solution Approach 1:
The patent uses peptides as intermediary molecules that bind to CD40 and prevent CD154 from interacting with it. These peptides act as mediators that block the harmful CD40-CD154 interaction, thereby preventing immune response activation and rejection while maintaining the therapeutic effect.
Solution Approach 2:
The patent extracts and isolates specific peptide sequences that are capable of binding to CD40 and inhibiting its interaction with CD154. By separating and purifying these functional peptides from other cellular components, the invention creates a targeted therapeutic agent that specifically blocks the harmful interaction without affecting other immune functions.
2Reliability
If peptides are designed to bind CD40 with high affinity, then the inhibition of CD40-CD154 interaction is improved, but the peptide sequence complexity increases
Solution Approach 1:
The patent divides the CD40 binding interface into specific peptide segments or motifs that are responsible for high-affinity binding. By identifying and isolating these specific segments rather than requiring the entire CD40 protein, the invention achieves high binding affinity while maintaining relatively simple peptide sequences that are easier to synthesize and administer.
Data Source
AI summary
The present disclosure is related to compositions comprising peptides that bind CD40 and methods of use in inhibiting interaction of CD40 and CD154 and inducing immunosuppression. Provided herein are methods of transplantation and methods of inhibiting donor specific immune response. Also provided herein are methods of treatment for autoimmune diseases, inflammatory diseases and cancer.